Carcinoma News and Research

RSS
Carcinoma is cancer that begins in the skin or in tissues that line or cover internal organs.
Final analysis of AVEO's tivozanib Phase 2 trial on kidney cancer patients presented at ASCO 2011

Final analysis of AVEO's tivozanib Phase 2 trial on kidney cancer patients presented at ASCO 2011

AVEO’s ficlatuzumab-gefitinib Phase 1b/2 trial data against NSCLC to be presented at ASCO 2011

AVEO’s ficlatuzumab-gefitinib Phase 1b/2 trial data against NSCLC to be presented at ASCO 2011

Lymphocyte count serves as simple and effective prognostic indicator in renal cell carcinoma

Lymphocyte count serves as simple and effective prognostic indicator in renal cell carcinoma

EMA accepts Pfizer's filing of axitinib for regulatory review to treat advanced renal cell carcinoma

EMA accepts Pfizer's filing of axitinib for regulatory review to treat advanced renal cell carcinoma

IPSOGEN announces two studies on Genomic Grade test to be presented at ASCO 2011

IPSOGEN announces two studies on Genomic Grade test to be presented at ASCO 2011

Centocor Ortho Biotech, AVEO sign license deal to develop, commercialize RON-targeted antibodies

Centocor Ortho Biotech, AVEO sign license deal to develop, commercialize RON-targeted antibodies

Innovations in diagnosis and treatment for esophageal cancer

Innovations in diagnosis and treatment for esophageal cancer

Pan-Canadian surgical study offers new hope for patients with early-stage oral cancer

Pan-Canadian surgical study offers new hope for patients with early-stage oral cancer

ImmunoGen's clinical data on IMGN901 and SAR3419 to be presented at ASCO 2011

ImmunoGen's clinical data on IMGN901 and SAR3419 to be presented at ASCO 2011

Boehringer Ingelheim's new afatinib-cetuximab phase Ib data in NSCLC presented at ASCO 2011

Boehringer Ingelheim's new afatinib-cetuximab phase Ib data in NSCLC presented at ASCO 2011

Ardea reports additional results from lesinurad-allopurinol Phase 2b study in hyperuricemia, gout

Ardea reports additional results from lesinurad-allopurinol Phase 2b study in hyperuricemia, gout

Positive preliminary results from Genomic Health's Oncotype DX study in DCIS breast cancer

Positive preliminary results from Genomic Health's Oncotype DX study in DCIS breast cancer

Patient accrual complete in Provectus PH-10 Phase 2C clinical trial for treatment of psoriasis

Patient accrual complete in Provectus PH-10 Phase 2C clinical trial for treatment of psoriasis

VBL to present updated VB-111 Phase 1 trial results in advanced metastatic cancer at ASCO 2011

VBL to present updated VB-111 Phase 1 trial results in advanced metastatic cancer at ASCO 2011

Vertex Incivek receives FDA approval for treatment of chronic hepatitis C

Vertex Incivek receives FDA approval for treatment of chronic hepatitis C

FDA approves SUTENT for treatment of pancreatic NET

FDA approves SUTENT for treatment of pancreatic NET

Data from Seattle Genetics' brentuximab vedotin, SGN-75 programs to be presented at ASCO 2011

Data from Seattle Genetics' brentuximab vedotin, SGN-75 programs to be presented at ASCO 2011

FDA approves Sutent for patients with progressive neuroendocrine cancerous tumors in pancreas

FDA approves Sutent for patients with progressive neuroendocrine cancerous tumors in pancreas

EMA CHMP recommends positive opinion for marketing authorization of Amgen's XGEVA

EMA CHMP recommends positive opinion for marketing authorization of Amgen's XGEVA

Jennerex presents positive preliminary data from JX-594 Phase 2 trial for advanced liver cancer

Jennerex presents positive preliminary data from JX-594 Phase 2 trial for advanced liver cancer

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.